Zonisamide for Weight Reduction in Obese Adults

Gadde, Kishore M.; Kopping, Mariko F.; Wagner, H. Ryan; Yonish, Gretchen M.; Allison, David B.; Bray, George A.

doi:10.1001/2013.jamainternmed.99

Cited by 71 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Zonisamide, an antiepileptic drug, was shown to enhance weight loss in obese adults in a short-term RCT [1]. Recently, Gadde et al reported results from a 12-month RCT in which daily treatment with zonisamide 400 mg was showed to be more effective than placebo or zonisamide 200 mg [2]. In this paper, we report weight changes at 6-months after discontinuation of lifestyle counselling and double-blind zonisamide or placebo.…”

Section: Introductionmentioning

confidence: 81%

“…The study was conducted at Duke University Medical Center after institutional review board approval. This was an extension of a 12-month RCT (ClinicalTrials.gov Identifier: NCT00275834); eligibility criteria and details of the study design and conduct were described a previous publication [2]. The first phase was a randomised, double-blind, placebocontrolled trial in which a total 225 obese men and women without diabetes mellitus [mean body mass index standard deviation (SD), 37.6 [4.9] kg/m 2 ] were randomly assigned to treatment with daily placebo, zonisamide 200 mg or zonisamide 400 mg for 12-months, when all study interventions and monthly assessments were discontinued.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Weight changes in obese adults 6‐months after discontinuation of double‐blind zonisamide or placebo treatment

Shin

Gadde

Østbye

et al. 2014

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

We evaluated weight changes in obese patients at 6-months after they ended participation in a 12-month randomized controlled trial in which they received daily placebo, zonisamide 200 mg, or zonisamide 400 mg, in addition to lifestyle counseling. Of the originally randomized 225 patients, 218 completed month-12 when study interventions were discontinued. For the 154 patients who returned for 6-month follow-up off-treatment, weight changes between month-12 and month-18 for placebo (n=53), zonisamide 200 mg (n=49), and zonisamide 400 mg groups (n=52) were 0.5 kg (95% CI, −0.8 to 1.8; 0.7%), 1.5 kg (0.2 to 2.8; 1.6%; p=0.26 vs placebo) and 2.4 kg (1.1 to 3.7; 2.6%; p=0.04 vs placebo), respectively. Our results suggest that although zonisamide 400 mg daily for 12-months resulted in greater weight loss than with placebo, weight regain after discontinuation of interventions was greater in the zonisamide 400 mg group than placebo group.

show abstract

Section: Introductionmentioning

confidence: 81%

Section: Methodsmentioning

confidence: 99%

Weight changes in obese adults 6‐months after discontinuation of double‐blind zonisamide or placebo treatment

Shin

Gadde

Østbye

et al. 2014

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Zonisamide is not approved for use for weight loss by the FDA. Zonisamide has not been found to have any adverse CV side effects, and has been associated with a decrease in BP and HR (43,70). From a CV standpoint, topiramate and zonisamide appear to be safe, and do not appear to be associated with increased CV risk.…”

Section: Anti-epileptic Medicationsmentioning

confidence: 99%

Cardiovascular Risks and Benefits of Medications Used for Weight Loss

et al. 2020

View full text Add to dashboard Cite

Obesity is a complex disease influenced by many neurohormonal pathways which regulate body weight toward homeostasis. Presently, the disease of obesity effects over a billion individuals worldwide with scalable treatment options in dire need. Pharmacologic interventions for obesity have been developed to help promote weight loss in individuals with obesity. This area is rapidly developing and will only exponentially increase to serve the demand for persons with obesity seeking biologically orientated solutions to treat their disease. Therefore, understanding the cardiovascular risks and benefits of these weight loss medications is of particularly importance due to obesities strong association with cardiovascular (CV) disease risk. Moreover, past experiences with pharmacotherapy agents with weight loss properties have demonstrated an association with adverse CV outcomes, leading to market removal, in most cases and concerns over using similar medications. To better understand the CV risks and benefits pharmacotherapy agents used for weight loss, this review will discuss medications which are FDA-approved for weight loss, as well as medications commonly used off-label for this indication. The goal is to provide an overview of the risks and benefits many of these medications can offer to help guide clinical decision making and patient education.

show abstract

“…В 2012 г. в двойном слепом плацебо-контролируемом исследовании, длившемся на протяжении года, в качестве средства для снижения веса у людей с избыточной массой тела также использовался зонисамид [34]. Стоит отметить, что эффективной была доза 400 мг в сутки, тогда как доза препарата 200 мг в сутки не показала существенного отличия от плацебо.…”

Section: зонисамидunclassified

Current trends in the use of anticonvulsants in psychiatric practice

Demyanov¹,

Сурикова²,

Melnik³

2017

Vestnik SPbSU. Medicine

View full text Add to dashboard Cite

В обзорной статье рассмотрены современные тенденции применения антиконвульсантов в психиатрической практике, являющиеся малоизученной и редко затрагиваемой проблемой, за исключением вопросов терапии биполярного расстройства. Кратко описаны основные особенности группы препаратов. Представлены данные зарубежных исследований по основным антиконвульсантам. Рассмотрены результаты как крупных метаанализов, так и открытых исследований с малым количеством пациентов, демонстрирующие основные направления научных изысканий по данной тематике. Приведенные данные могут стать основой не только для дальнейших исследований, но и для осмотрительного и разумного применения в клинической практике, особенно в сложных, труднокурабельных случаях, требующих от врача максимально широкого кругозора и знания современных тенденций в психиатрии. Библиогр. 55 назв.Ключевые слова: антиконвульсанты, психофармакотерапия, психиатрия, шизофрения, расстройства пищевого поведения.The goal of the review article is to examine current trends in psychiatric practice regarding the use of anticonvulsants that are not related to the treatment of bipolar disorder. The article provides a brief description of the main characteristics of this class of drugs and discusses findings of international studies on the major anticonvulsants. The summary of the results of large meta-analyses as well as open data of studies with a small number of participants demonstrates the main trends in scientific research on the subject. Refs 55. ВведениеПостоянный прогресс психофармакологии приводит к появлению новых лекарственных средств, из-за чего значение старых, хорошо изученных препаратов незаслуженно уменьшается. При этом зачастую специалисты используют их в тех дозировках и при тех клинических состояниях, при которых они привыкли назначать данные препараты. Вероятно, именно с этим связано недостаточное внимание к появлению новых показаний у лекарственных средств со стороны специалистов.

show abstract

Zonisamide for Weight Reduction in Obese Adults

Cited by 71 publications

References 22 publications

Weight changes in obese adults 6‐months after discontinuation of double‐blind zonisamide or placebo treatment

Weight changes in obese adults 6‐months after discontinuation of double‐blind zonisamide or placebo treatment

Cardiovascular Risks and Benefits of Medications Used for Weight Loss

Current trends in the use of anticonvulsants in psychiatric practice

Contact Info

Product

Resources

About